Time-dependent changes in mortality and transformation risk in MDS

Michael Pfeilstöcker, Heinz Tuechler, Guillermo Sanz, Julie Schanz, Guillermo Garcia-Manero, Francesc Solé, John M. Bennett, David Bowen, Pierre Fenaux, Francois Dreyfus, Hagop Kantarjian, Andrea Kuendgen, Luca Malcovati, Mario Cazzola, Jaroslav Cermak, Christa Fonatsch, Michelle M. Le Beau, Marilyn L. Slovak, Alessandro Levis, Michael LuebbertJaroslaw Maciejewski, Sigrid Machherndl-Spandl, Silvia M M Magalhaes, Yasushi Miyazaki, Mikkael A. Sekeres, Wolfgang R. Sperr, Reinhard Stauder, Sudhir Tauro, Peter Valent, Teresa Vallespi, Arjan A. Van De Loosdrecht, Ulrich Germing, Detlef Haase, Peter L. Greenberg

Research output: Contribution to journalArticle

Abstract

In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower- and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.

Original languageEnglish
Pages (from-to)902-910
Number of pages9
JournalBlood
Volume128
Issue number7
DOIs
Publication statusPublished - Aug 18 2016

Fingerprint

Myelodysplastic Syndromes
Mortality
Hazards
Survival
Acute Myeloid Leukemia
Multicenter Studies

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Pfeilstöcker, M., Tuechler, H., Sanz, G., Schanz, J., Garcia-Manero, G., Solé, F., ... Greenberg, P. L. (2016). Time-dependent changes in mortality and transformation risk in MDS. Blood, 128(7), 902-910. https://doi.org/10.1182/blood-2016-02-700054

Time-dependent changes in mortality and transformation risk in MDS. / Pfeilstöcker, Michael; Tuechler, Heinz; Sanz, Guillermo; Schanz, Julie; Garcia-Manero, Guillermo; Solé, Francesc; Bennett, John M.; Bowen, David; Fenaux, Pierre; Dreyfus, Francois; Kantarjian, Hagop; Kuendgen, Andrea; Malcovati, Luca; Cazzola, Mario; Cermak, Jaroslav; Fonatsch, Christa; Le Beau, Michelle M.; Slovak, Marilyn L.; Levis, Alessandro; Luebbert, Michael; Maciejewski, Jaroslaw; Machherndl-Spandl, Sigrid; Magalhaes, Silvia M M; Miyazaki, Yasushi; Sekeres, Mikkael A.; Sperr, Wolfgang R.; Stauder, Reinhard; Tauro, Sudhir; Valent, Peter; Vallespi, Teresa; Van De Loosdrecht, Arjan A.; Germing, Ulrich; Haase, Detlef; Greenberg, Peter L.

In: Blood, Vol. 128, No. 7, 18.08.2016, p. 902-910.

Research output: Contribution to journalArticle

Pfeilstöcker, M, Tuechler, H, Sanz, G, Schanz, J, Garcia-Manero, G, Solé, F, Bennett, JM, Bowen, D, Fenaux, P, Dreyfus, F, Kantarjian, H, Kuendgen, A, Malcovati, L, Cazzola, M, Cermak, J, Fonatsch, C, Le Beau, MM, Slovak, ML, Levis, A, Luebbert, M, Maciejewski, J, Machherndl-Spandl, S, Magalhaes, SMM, Miyazaki, Y, Sekeres, MA, Sperr, WR, Stauder, R, Tauro, S, Valent, P, Vallespi, T, Van De Loosdrecht, AA, Germing, U, Haase, D & Greenberg, PL 2016, 'Time-dependent changes in mortality and transformation risk in MDS', Blood, vol. 128, no. 7, pp. 902-910. https://doi.org/10.1182/blood-2016-02-700054
Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016 Aug 18;128(7):902-910. https://doi.org/10.1182/blood-2016-02-700054
Pfeilstöcker, Michael ; Tuechler, Heinz ; Sanz, Guillermo ; Schanz, Julie ; Garcia-Manero, Guillermo ; Solé, Francesc ; Bennett, John M. ; Bowen, David ; Fenaux, Pierre ; Dreyfus, Francois ; Kantarjian, Hagop ; Kuendgen, Andrea ; Malcovati, Luca ; Cazzola, Mario ; Cermak, Jaroslav ; Fonatsch, Christa ; Le Beau, Michelle M. ; Slovak, Marilyn L. ; Levis, Alessandro ; Luebbert, Michael ; Maciejewski, Jaroslaw ; Machherndl-Spandl, Sigrid ; Magalhaes, Silvia M M ; Miyazaki, Yasushi ; Sekeres, Mikkael A. ; Sperr, Wolfgang R. ; Stauder, Reinhard ; Tauro, Sudhir ; Valent, Peter ; Vallespi, Teresa ; Van De Loosdrecht, Arjan A. ; Germing, Ulrich ; Haase, Detlef ; Greenberg, Peter L. / Time-dependent changes in mortality and transformation risk in MDS. In: Blood. 2016 ; Vol. 128, No. 7. pp. 902-910.
@article{7733d3115e384dac8b02e822057d92a7,
title = "Time-dependent changes in mortality and transformation risk in MDS",
abstract = "In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower- and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.",
author = "Michael Pfeilst{\"o}cker and Heinz Tuechler and Guillermo Sanz and Julie Schanz and Guillermo Garcia-Manero and Francesc Sol{\'e} and Bennett, {John M.} and David Bowen and Pierre Fenaux and Francois Dreyfus and Hagop Kantarjian and Andrea Kuendgen and Luca Malcovati and Mario Cazzola and Jaroslav Cermak and Christa Fonatsch and {Le Beau}, {Michelle M.} and Slovak, {Marilyn L.} and Alessandro Levis and Michael Luebbert and Jaroslaw Maciejewski and Sigrid Machherndl-Spandl and Magalhaes, {Silvia M M} and Yasushi Miyazaki and Sekeres, {Mikkael A.} and Sperr, {Wolfgang R.} and Reinhard Stauder and Sudhir Tauro and Peter Valent and Teresa Vallespi and {Van De Loosdrecht}, {Arjan A.} and Ulrich Germing and Detlef Haase and Greenberg, {Peter L.}",
year = "2016",
month = "8",
day = "18",
doi = "10.1182/blood-2016-02-700054",
language = "English",
volume = "128",
pages = "902--910",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Time-dependent changes in mortality and transformation risk in MDS

AU - Pfeilstöcker, Michael

AU - Tuechler, Heinz

AU - Sanz, Guillermo

AU - Schanz, Julie

AU - Garcia-Manero, Guillermo

AU - Solé, Francesc

AU - Bennett, John M.

AU - Bowen, David

AU - Fenaux, Pierre

AU - Dreyfus, Francois

AU - Kantarjian, Hagop

AU - Kuendgen, Andrea

AU - Malcovati, Luca

AU - Cazzola, Mario

AU - Cermak, Jaroslav

AU - Fonatsch, Christa

AU - Le Beau, Michelle M.

AU - Slovak, Marilyn L.

AU - Levis, Alessandro

AU - Luebbert, Michael

AU - Maciejewski, Jaroslaw

AU - Machherndl-Spandl, Sigrid

AU - Magalhaes, Silvia M M

AU - Miyazaki, Yasushi

AU - Sekeres, Mikkael A.

AU - Sperr, Wolfgang R.

AU - Stauder, Reinhard

AU - Tauro, Sudhir

AU - Valent, Peter

AU - Vallespi, Teresa

AU - Van De Loosdrecht, Arjan A.

AU - Germing, Ulrich

AU - Haase, Detlef

AU - Greenberg, Peter L.

PY - 2016/8/18

Y1 - 2016/8/18

N2 - In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower- and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.

AB - In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower- and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.

UR - http://www.scopus.com/inward/record.url?scp=84983344821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983344821&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-02-700054

DO - 10.1182/blood-2016-02-700054

M3 - Article

AN - SCOPUS:84983344821

VL - 128

SP - 902

EP - 910

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -